Show simple item record

dc.contributor.authorAnanthakrishnan, Ashwin N.
dc.contributor.authorCagan, Andrew
dc.contributor.authorGainer, Vivian S.
dc.contributor.authorCheng, Su-Chun
dc.contributor.authorCai, Tianxi
dc.contributor.authorSzolovits, Peter
dc.contributor.authorShaw, Stanley Y.
dc.contributor.authorChurchill, Susanne
dc.contributor.authorKarlson, Elizabeth W.
dc.contributor.authorMurphy, Shawn N.
dc.contributor.authorKohane, Isaac
dc.contributor.authorLiao, Katherine P.
dc.date.accessioned2016-02-02T02:00:26Z
dc.date.available2016-02-02T02:00:26Z
dc.date.issued2014-09
dc.date.submitted2014-01
dc.identifier.issn1873-9946
dc.identifier.issn1876-4479
dc.identifier.urihttp://hdl.handle.net/1721.1/101052
dc.description.abstractIntroduction Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) frequently co-occur. PSC is associated with increased risk for colorectal cancer (CRC). However, whether PSC is associated with increased risk of extraintestinal cancers or affects mortality in an IBD cohort has not been examined previously. Methods In a multi-institutional IBD cohort of IBD, we established a diagnosis of PSC using a novel algorithm incorporating narrative and codified data with high positive and negative predictive value. Our primary outcome was occurrence of extraintestinal and digestive tract cancers. Mortality was determined through monthly linkage to the social security master death index. Results In our cohort of 5506 patients with CD and 5522 patients with UC, a diagnosis of PSC was established in 224 patients (2%). Patients with IBD–PSC were younger and more likely to be male compared to IBD patients without PSC; three-quarters had UC. IBD–PSC patients had significantly increased overall risk of cancers compared to patients without PSC (OR 4.36, 95% CI 2.99–6.37). Analysis of specific cancer types revealed that a statistically significant excess risk for digestive tract cancer (OR 10.40, 95% CI 6.86–15.76), pancreatic cancer (OR 11.22, 95% CI 4.11–30.62), colorectal cancer (OR 5.00, 95% CI 2.80–8.95), and cholangiocarcinoma (OR 55.31, 95% CI 22.20–137.80) but not for other solid organ or hematologic malignancies. Conclusions PSC is associated with increased risk of colorectal and pancreatobiliary cancer but not with excess risk of other solid organ cancers.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (U54-LM008748)en_US
dc.language.isoen_US
dc.publisherElsevieren_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/j.crohns.2014.01.019en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourcePMCen_US
dc.titleMortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel diseaseen_US
dc.typeArticleen_US
dc.identifier.citationAnanthakrishnan, Ashwin N., Andrew Cagan, Vivian S. Gainer, Su-Chun Cheng, Tianxi Cai, Peter Szolovits, Stanley Y. Shaw, et al. “Mortality and Extraintestinal Cancers in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.” Journal of Crohn’s and Colitis 8, no. 9 (September 1, 2014): 956–963.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Electrical Engineering and Computer Scienceen_US
dc.contributor.mitauthorSzolovits, Peteren_US
dc.relation.journalJournal of Crohn's and Colitisen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsAnanthakrishnan, Ashwin N.; Cagan, Andrew; Gainer, Vivian S.; Cheng, Su-Chun; Cai, Tianxi; Szolovits, Peter; Shaw, Stanley Y.; Churchill, Susanne; Karlson, Elizabeth W.; Murphy, Shawn N.; Kohane, Isaac; Liao, Katherine P.en_US
dc.identifier.orcidhttps://orcid.org/0000-0001-8411-6403
mit.licensePUBLISHER_CCen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record